value - The stock trades at 1.9x P/S and 9.1x EV/EBITDA with 8.4% FCF yield, attracting value investors seeking cash-generative healthcare…
Rising interest rates have minimal direct impact on operations given the company's low debt load (0.08 D/E ratio) and strong cash position.
Watch on earnings: CMS reimbursement rates for HCPCS codes Q4100-Q4226 (skin substitute products) and any proposed rule changes, Quarterly revenue growth rate versus mid-single-digit industry wound care market growth, Gross margin percentage trends indicating pricing pressure or favorable product mix.
One Sentence Summary:
MiMedx: the story is balanced — medicare/cms reimbursement policy changes for skin substitute products and hcpcs code coverage determinations.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.